Pricing Log in Create free account
Saturday 17 October 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.

218.01 18.49 −7.82%
Market cap
$94.4B
P/E
0.0×
Fwd P/E
−5.5×
Dividend yield
—
F-score
3/9
Altman Z
2.46
Beneish M
−3.52
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Moderna, Inc. 8-K filed Sep 1, 2026

Period ended Aug 27, 2026 · Filed · accepted 4:37 PM ET · Document on sec.gov · Filing index

1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 3.02 Unregistered sales of equity securities; 8.01 Other events; 9.01 Financial statements and exhibits